Abstract
Bromides are no longer a mainstay of epilepsy therapy because of the significant toxicity associated with their use and the availability of safer agents. However, bromides occasionally find a niche in the treatment of patients with refractory seizures, particularly in pediatrics. When the decision to utilize this therapy is made, the clinician may be frustrated by the lack of concise, current information regarding bromides. This review provides an update on the mechanism of action, efficacy, pharmacokinetics, dose, and adverse effects of bromides. Copyright (C) 1999 Elsevier Science Inc.
| Original language | English |
|---|---|
| Pages (from-to) | 523-528 |
| Number of pages | 6 |
| Journal | Pediatric Neurology |
| Volume | 21 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 1999 |
Bibliographical note
Funding Information:This work is financially supported by the European project TECHNEAU and Agence de l’eau Seine— Normandie (AESN). Long and useful discussions we had with Pascal Roche, David Benanou and Karine Drouet are greatly appreciated.
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Neurology
- Developmental Neuroscience
- Clinical Neurology